Lexicon Pharmaceuticals (NASDAQ:LXRX) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report released on Monday,Benzinga reports. The firm currently has a $4.00 price target on the biopharmaceutical company’s stock.

Separately, Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Wednesday, January 29th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $2.50.

Lexicon Pharmaceuticals Stock Performance

NASDAQ LXRX opened at $0.34 on Monday. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. Lexicon Pharmaceuticals has a 1 year low of $0.28 and a 1 year high of $2.83. The company has a market capitalization of $82.74 million, a PE ratio of -0.45 and a beta of 1.04. The company has a fifty day moving average of $0.74 and a two-hundred day moving average of $1.16.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. FMR LLC boosted its stake in shares of Lexicon Pharmaceuticals by 28.9% during the third quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock worth $78,291,000 after buying an additional 11,179,919 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Lexicon Pharmaceuticals by 4.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,417,295 shares of the biopharmaceutical company’s stock worth $2,225,000 after buying an additional 58,147 shares during the period. XTX Topco Ltd acquired a new stake in shares of Lexicon Pharmaceuticals during the third quarter worth about $126,000. Geode Capital Management LLC boosted its stake in shares of Lexicon Pharmaceuticals by 8.4% during the third quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company’s stock worth $5,534,000 after buying an additional 273,436 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Lexicon Pharmaceuticals during the third quarter worth about $189,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.